Aurobindo Pharma experienced an increase of 1.14%, reaching Rs 1,113.55, following the establishment of a new wholly owned subsidiary in Chile, named Eugia Pharma Chile SpA, by its wholly owned step-down subsidiary, Eugia Pharma B.V.
Johnson & Johnson announced impressive outcomes for a subcutaneous formulation of amivantamab (Rybrevant) which achieved a 45% overall response rate (ORR) in individuals with advanced head and neck squamous cell carcinoma (HNSCC)...
Glenmark Pharmaceuticals Inc., USA, has announced the upcoming launch of its Ropivacaine Hydrochloride Injection USP in three single-dose vial strengths
Alembic Pharmaceuticals Limited has secured final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Triamcinolone Acetonide Injectable Suspension USP
Roche revealed promising results from two pivotal Phase III trials, MEERKAT and SANDCAT, assessing vamikibart, an investigational non-steroidal medication for uveitic macular edema (UME). UME is attributable to inflammation and an accumulation...
Novartis announced that Cosentyx met its primary endpoint and all secondary endpoints in the Phase III REPLENISH study, a significant milestone in the treatment of polymyalgia rheumatica. At Week 52, Cosentyx demonstrated statistically...
Xavier School of Management, Jamshedpur, was the venue of a distinguished leadership session with Jacob Jacob, Group Chief Human Resources Officer of Aster DM Healthcare, Dubai, as part of the Aster NextGen Management
Superhealth, the first hospital network in India to offer zero wait times and zero commissions, has today announced a significant strategic partnership with the global imaging innovator, United Imaging Healthcare
Novo Nordisk's primary investor has taken steps to gain control of the pharmaceutical company's board, pledging to concentrate more on the crucial U.S. market in order to rejuvenate sales of the highly successful weight-loss medication Wegovy, follow
In patients with advanced endometrial cancer, five-year data from the Phase 3 KEYNOTE-775/Study 309 trial revealed a durable survival benefit for KEYTRUDA plus LENVIMA compared to chemotherapy, according to Merck, which is known as MSD outside of the
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")